| Display title | Chemistry:SDB-005 |
| Default sort key | SDB-005 |
| Page length (in bytes) | 3,517 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 38803 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>BotanyGa |
| Date of page creation | 21:09, 17 December 2022 |
| Latest editor | imported>BotanyGa |
| Date of latest edit | 21:09, 17 December 2022 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | SDB-005 is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22 where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code... |
